Quantrx Biomedical (Quantrx Biomedical) EBIT : $-0.05 Mil (TTM As of Sep. 2022)

View and export this data going back to . Start your Free Trial

What is Quantrx Biomedical EBIT?

Quantrx Biomedical's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2022 was $-0.01 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2022 was $-0.05 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Quantrx Biomedical's annualized ROC % for the quarter that ended in Sep. 2022 was -1.02%. Quantrx Biomedical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2022 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Quantrx Biomedical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2022 was -1.41%.

Quantrx Biomedical EBIT Historical Data

The historical data trend for Quantrx Biomedical's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quantrx Biomedical EBIT Chart

Quantrx Biomedical Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

EBIT

Get a 7-Day Free Trial

1.12

-0.51

-0.42

-0.04

Quantrx Biomedical Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
EBIT	Get a 7-Day Free Trial															-0.01	-0.01	-	-0.03	-0.01

Competitive Comparison of Quantrx Biomedical's EBIT

For the Medical Instruments & Supplies subindustry, Quantrx Biomedical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Quantrx Biomedical's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Quantrx Biomedical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Quantrx Biomedical's EV-to-EBIT falls into.

Quantrx Biomedical EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.05 Mil.

Quantrx Biomedical (OTCPK:QTXB) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Quantrx Biomedical's annualized ROC % for the quarter that ended in Sep. 2022 is calculated as:

	ROC % (Q: Sep. 2022 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2022 )	+	Invested Capital (Q: Sep. 2022 ))	/ count )
=	-0.028 * ( 1 - 0% )	/	( (2.682	+	2.83)	/ 2 )
=	-0.028	/	2.756
=	-1.02 %

where

	Invested Capital		(Q: Jun. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.005	-	0.102	-	( 0.002	-	max(0, 2.784	-	0.005	+	0.002	))
=	2.682

	Invested Capital		(Q: Sep. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0.005	-	0.016	-	( 0.004	-	max(0, 2.846	-	0.005	+	0.004	))
=	2.83

Note: The Operating Income data used here is four times the quarterly (Sep. 2022) data.

2. Joel Greenblatt's definition of Return on Capital:

Quantrx Biomedical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2022 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2022 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2022		Q: Sep. 2022
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-0.028	/	( ( (0 + max(-0.098, 0))	+	(0 + max(-0.016, 0)) )	/	2 )
=	-0.028	/	( ( 0	+	0 )	/	2 )
=	-0.028	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Jun. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.003)	-	(0.102	+	0	+	-0.00099999999999989)
=	-0.098

	Working Capital		(Q: Sep. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.001)	-	(0.016	+	0	+	0.00099999999999989)
=	-0.016

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2022) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Quantrx Biomedical's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2022 )
	=	-0.045	/	3.202
	=	-1.41 %

Quantrx Biomedical EBIT Related Terms

Thank you for viewing the detailed overview of Quantrx Biomedical's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Quantrx Biomedical (Quantrx Biomedical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Quantrx Biomedical Corp (OTCPK:QTXB) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

10190 SW 90th Avenue, Tualatin, OR, USA, 97062

Website

http://www.quantrx.com

Quantrx Biomedical Corp operates towards the development and commercialization of patented mini form pad (PAD) based products. The PAD products are based on the company's non-woven disposable absorbent pad technology and it is involved in the PAD-based over-the-counter products for the treatment of hemorrhoids, minor vaginal infection, urinary incontinence, general catamenial uses, and other medical needs. Its platforms include inSync(R), Unique(TM), and OEM branded over-the-counter and laboratory testing products.

Executives

Michael S Abrams	director	64 RAMSHEAD ROAD, RAYNHAM MA 02767
Patrick T Mooney	director	C/O SONTRA MEDICAL CORPORATION, 10 FORGE PARKWAY, FRANKLIN MA 02038
Robert G. Pinco	director	1700 K STREET NW, SUITE 300, WASHINGTON DC 20006
Hayes Arthur H Jr	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Matthew Balk	10 percent owner	229 WEST 60TH STREET, NEW YORK NY 10023
Evan Levine	director, 10 percent owner	1517 SAN JACINTO ST., HOUSTON TX 77002
Hayes Arthur Hull Jr	director	C/O QUANTRX BIOMEDICAL CORPORATION, 100 S. MAIN STREET, SUITE 300, DOYLESTOWN PA 18901
Cindy Horton	officer: V.P. of Diagnostics	209 BRITTANY PARK, ANDERSON SC 29621
Sasha Afanassiev	officer: Officer	120 GARRISON COURT, LANGHORNE PA 19047
Shalom Hirschman	officer: Officer	5240 BLACKSTONE AVENUE, RIVERDALE NY 10471
William H Fleming	director, officer: Secretary
Walter W Witoshkin	director, officer: President and CEO	321 NORRISTOWN ROAD, SUITE 230, AMBLE PA 19002
Mark Capital Llc	10 percent owner	5173 SEAGROVE PLACE, SAN DIEGO CA 92130
Sherbrooke Partners, Llc	10 percent owner	570 LEXINGTON AVENUE, FLOOR 3, NEW YORK NY 10022
Goldman Sachs & Co. Llc	10 percent owner	200 WEST STREET, NEW YORK NY 10282

Quantrx Biomedical (Quantrx Biomedical) Headlines

No Headlines